Tag: AliveCor

  • AliveCor Launches KardiaMobile 6L Max Portable ECG for Smartphones

    AliveCor Launches KardiaMobile 6L Max Portable ECG for Smartphones

    Key Takeaways

    1. Advanced ECG Technology: The KardiaMobile 6L Max uses a 6-lead ECG system to provide more detailed heart health information compared to standard smartwatches.

    2. Early Heart Issue Detection: The device can identify various heart irregularities, reducing the need for expensive and time-consuming clinic visits for a full 12-lead ECG.

    3. KardiaCare Subscription: Users must subscribe to KardiaCare for continuous ECG analysis and access to certified cardiologists for early detection of heart problems.

    4. Quick and Convenient Use: The device connects via Bluetooth and can produce an ECG reading in just 30 seconds, with data sent to KardiaCare for evaluation through a compatible app.

    5. Pricing and Options: The KardiaMobile 6L Max is priced at $169 and will be available on Amazon, with additional portable variations offered.

    AliveCor has introduced its new KardiaMobile 6L Max, a portable ECG (electrocardiogram) device for smartphones, aimed at identifying heart issues early.

    Enhanced Data Capture

    The Max offers more valuable information than standard smartwatches by utilizing a straightforward 6-lead ECG system. This gadget can identify various heart irregularities, such as atrial fibrillation (AFib), bradycardia, tachycardia, and sinus rhythm with PVCs, SVE, and Wide QRS. This innovation can lessen the need for frequent visits to the clinic for a full 12-lead ECG, which often requires a lot of time and can be expensive.

    Subscription Service for Continuous Monitoring

    To benefit from this device, users must sign up for the KardiaCare subscription, which provides continuous ECG analysis. This includes assessments from certified cardiologists when needed, which can be crucial for spotting heart problems early on.

    The KardiaMobile 6L Max connects via Bluetooth and can produce an ECG reading in just 30 seconds. The corresponding app can then transmit this data to KardiaCare for further evaluation. The app is compatible with smartphones running Apple iOS 10.3.3 or newer and Android OS 6.0 or above. The device’s dimensions are 9.0 x 3.0 x 0.72 cm (3.5 x 1.2 x 0.28 in.), and it operates on a replaceable lithium coin battery that lasts for a whole year.

    Pricing and Availability

    The KardiaMobile 6L Max is priced at $169 and will be available shortly on the AliveCor store on Amazon. There are also other variations, including a credit card-sized KardiaMobile for easier portability.

    For those interested in understanding how modern diets have led to preventable deaths, especially with heart disease being the top cause of death in the U.S., a relevant book is available on Amazon.

    Source:
    Link

    Tags: , ,
  • Apple Wins Legal Battle Against AliveCor, Avoids Watch Import Ban

    Apple Wins Legal Battle Against AliveCor, Avoids Watch Import Ban

    Key Takeaways

    1. Apple won a significant patent dispute against AliveCor, preventing a potential ban on importing the Apple Watch.
    2. The U.S. Court of Appeals confirmed the invalidation of AliveCor’s ECG patents, which Apple was accused of infringing.
    3. The legal battle began in 2020 when AliveCor claimed Apple copied its ECG technology used in the Apple Watch.
    4. Apple successfully appealed to the U.S. Patent and Trademark Office, arguing that AliveCor’s patents lacked patentability due to prior art.
    5. AliveCor expressed disappointment with the ruling, claiming it harms smaller innovators and allows larger companies to dominate the market.

    Apple has emerged victorious once more in a significant patent dispute, achieving an important win against AliveCor in a case that could have resulted in a ban on importing the Apple Watch. The U.S. Court of Appeals for the Federal Circuit confirmed the invalidation of AliveCor’s patents today, wrapping up a lengthy legal battle that has seen the tech giant from Cupertino face off against a smaller medical technology firm that argues Apple exploited its innovations.

    Court Ruling Favors Apple, Disqualifying AliveCor’s ECG Patents

    The conflict traces back to 2020 when AliveCor charged Apple with violating its patents concerning ECG technology, which Apple incorporated into the Apple Watch starting with the Series 4 model. AliveCor is recognized for its KardiaBand accessory, which brought FDA-approved electrocardiogram features to the Apple Watch prior to Apple releasing its own version. The company claimed that the tech titan copied its innovations while also hindering third-party developers like AliveCor from freely functioning on its platform. AliveCor pushed for an import ban at the U.S. International Trade Commission (ITC), which initially ruled in its favor, deciding that Apple did infringe on its patents.

    Apple’s Resilience in Legal Battle

    Nevertheless, Apple wasn’t about to give in easily. The company appealed the matter to the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB), which ultimately sided with Apple, ruling that AliveCor’s patents lacked patentability due to existing prior art. This ruling weakened AliveCor’s position, and the Federal Circuit’s decision today solidifies the result: AliveCor’s patents will not hold up, and there will be no ban on importing the Apple Watch.

    AliveCor, as expected, is not pleased with the outcome. The company voiced its disappointment with the ruling, arguing that it endangers smaller innovators by enabling large corporations to monopolize the market without checks. For Apple, however, this represents yet another win in its quest to keep the Apple Watch as the leading device for health monitoring. In a related note, a separate import ban concerning Masimo’s blood oxygen technology for the Apple Watch is still in place—at least for the time being.

    Source:
    Link

    Tags: , ,